Other therapies, such as HER2-targeted drugs (trastuzumab), anti-angiogenesis drugs (VEGF monoclonal antibody ramucirumab and immunotherapy), and PD1 monoclonal antibodies (nivolumab and pembrolizumab) also play a more and more important role in advanced gastric cancer. The gene discussed is VEGFA; the disease is gastric cancer.